Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
8 p, 334.2 KB Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer : Retrospective Testing of Specimens from the EURTAC Trial / Benlloch, Susana (Pangaea Biotech) ; Botero, Maria Luisa (Pangaea Biotech) ; Beltran-Alamillo, Jordi (Pangaea Biotech) ; Mayo, Clara (Pangaea Biotech) ; Giménez-Capitán, Ana (Pangaea Biotech) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Klughammer, Barbara (F. Hoffmann-La Roche, Basel) ; Schlegel, Mariette (F. Hoffmann-La Roche, Basel) ; Bordogna, Walter (F. Hoffmann-La Roche, Basel) ; Chen, David (Genentech, South San Francisco, California) ; Zhang, Guili (Roche Molecular Systems, Pleasanton, California) ; Kovach, Barbara (Roche Molecular Systems, Pleasanton, California) ; Shieh, Felice (Roche Molecular Systems, Pleasanton, California) ; Palma, John F. (Roche Molecular Systems, Pleasanton, California) ; Wu, Lin (Roche Molecular Systems, Pleasanton, California) ; Lawrence, H. Jeffrey (Roche Molecular Systems, Pleasanton, California) ; Taron, Miquel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. [...]
2014 - 10.1371/journal.pone.0089518
PloS one, Vol. 9 (february 2014)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.